Please use this identifier to cite or link to this item:
|Title:||Expression of androgen receptor and its regulatory molecule lin28 in non-luminal subtype breast cancer|
Faculty of Medicine, Siriraj Hospital, Mahidol University
|Keywords:||Biochemistry, Genetics and Molecular Biology;Medicine|
|Citation:||Molecular and Clinical Oncology. Vol.12, No.6 (2020), 511-518|
|Abstract:||© 2020, Spandidos Publications. All rights reserved. Androgen receptor (AR) was associated with favourable outcome in luminal breast cancer. However, the role of AR in non-luminal breast cancer remains inconclusive. The aim of the present study was to evaluate the clinical significance of t he AR and its regulator y pat hway in non-luminal subtypes of breast cancer. In total, 284 breast cancer patients were recruited from January 2007 to January 2016. Tissue microarrays were constructed from archival paraffin blocks and assessed for AR and its regulatory molecule, Lin28, by immunohistochemistry. The association between AR and Lin28 expression and clinicopathological parameters was analyzed. Results showed that AR and Lin28 were co-expressed. No association between these proteins and clinicopathological parameters, and survival outcome was found. However, a higher proportion of the patients with AR and Lin28 expression were observed in HER2 subtype. In conclusion, Lin28 may be a novel marker for prognosis and targeted for treatment in HER2 subtype breast cancer.|
|Appears in Collections:||Scopus 2020|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.